Ken Griffin Beam Therapeutics Inc. Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 51,300 shares of BEAM stock, worth $1.72 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

51,300

Previous 92,900 44.78%

Holding current value

$1.72 Million

Previous $2.28 Million 44.11%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$21.55 - $30.35 $12.2 Million - $17.2 Million	566,051 Added 37.83%	2,062,246 $51.1 Million
Q3 2024 Nov 14, 2024	BUY	$22.57 - $33.14 $16.4 Million - $24.1 Million	727,041 Added 94.52%	1,496,195 $36.7 Million
Q2 2024 Aug 14, 2024	BUY	$21.22 - $32.66 $15.5 Million - $23.8 Million	729,641 Added 1846.58%	769,154 $18 Million
Q1 2024 May 15, 2024	BUY	$23.46 - $45.07 $658,475 - $1.27 Million	28,068 Added 245.24%	39,513 $1.31 Million
Q4 2023 Feb 14, 2024	SELL	$17.69 - $30.76 $20.6 Million - $35.8 Million	-1,165,470 Reduced 99.03%	11,445 $311,000
Q3 2023 Nov 14, 2023	BUY	$23.01 - $32.46 $19.7 Million - $27.8 Million	857,371 Added 268.31%	1,176,915 $28.3 Million
Q2 2023 Aug 14, 2023	BUY	$29.32 - $35.99 $4.06 Million - $4.98 Million	138,344 Added 76.35%	319,544 $10.2 Million
Q1 2023 May 15, 2023	BUY	$30.15 - $48.79 $1.57 Million - $2.53 Million	51,938 Added 40.18%	181,200 $5.55 Million
Q4 2022 Feb 14, 2023	BUY	$36.73 - $51.6 $1.28 Million - $1.8 Million	34,930 Added 37.03%	129,262 $5.06 Million
Q3 2022 Nov 14, 2022	BUY	$39.79 - $70.31 $1.63 Million - $2.88 Million	41,000 Added 76.88%	94,332 $4.49 Million
Q2 2022 Aug 15, 2022	SELL	$29.86 - $62.36 $3.32 Million - $6.93 Million	-111,186 Reduced 67.58%	53,332 $2.06 Million
Q1 2022 May 16, 2022	BUY	$53.73 - $82.16 $4.5 Million - $6.88 Million	83,789 Added 103.79%	164,518 $9.43 Million
Q4 2021 Feb 14, 2022	SELL	$68.02 - $99.06 $9.21 Million - $13.4 Million	-135,463 Reduced 62.66%	80,729 $6.43 Million
Q3 2021 Nov 15, 2021	BUY	$84.37 - $133.6 $16.4 Million - $26 Million	194,580 Added 900.33%	216,192 $18.8 Million
Q2 2021 Aug 16, 2021	SELL	$64.12 - $128.71 $8.7 Million - $17.5 Million	-135,705 Reduced 86.26%	21,612 $2.78 Million
Q1 2021 May 17, 2021	BUY	$71.28 - $120.75 $10.5 Million - $17.8 Million	147,684 Added 1533.1%	157,317 $12.6 Million
Q4 2020 Feb 16, 2021	BUY	$22.24 - $95.63 $214,237 - $921,203	9,633 New	9,633 $786,000
Q3 2020 Nov 16, 2020	SELL	$19.0 - $30.57 $515,394 - $829,241	-27,126 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$15.26 - $28.66 $902,979 - $1.7 Million	-59,173 Reduced 68.57%	27,126 $759,000
Q1 2020 May 15, 2020	BUY	$13.31 - $29.2 $1.15 Million - $2.52 Million	86,299 New	86,299 $1.55 Million

Others Institutions Holding BEAM

# of Institutions

251

Shares Held

78.6M

Call Options Held

304K

Put Options Held

142K

View Full List

About Beam Therapeutics Inc.

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $2.36B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

More about BEAM

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account